Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.

NCT06293378 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Chongqing Medical University as lead sponsor.

NCT NCT06293378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06293378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.
Lead sponsor
The Second Affiliated Hospital of Chongqing Medical University
Phase
Not applicable
Overall status
Recruiting
Start date
February 1, 2024
Completion date
October 10, 2028
Enrollment
330 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, liver, fibrosis, liver